A strong intellectual property portfolio is one of the most important assets for a life sciences company. Over the last year, a perfect legal and regulatory storm has been unleashed on the life sciences industry and is greatly impacting IP Due Diligence.
ACI’s 7th Annual Life Sciences IP Due Diligence Summit is devoted to providing corporate and IP counsel with the tools and critical information you need to develop winning strategies and ensure strong, valuable, and protected IP Assets that can hold up under pressure. Our esteemed speakers will provide insights on what to look for during the due diligence process, how to strategize in a shifting landscape, and how to avoid potential patent pitfalls.
CONFERENCE CO-CHAIRS
Tom Irving
Partner
The Marbury Law Group, PLLC
Forrester Liddle
Head of Intellectual Property and Legal for US R&D
Novo Nordisk
SPECIAL SESSION ON IP DUE DILIGENCE IN THE AGE OF AI WITH
Charles Kim
Deputy Commissioner for Patents
United States Patent and Trademark Office
GAIN INSIGHTS FROM KEY INDUSTRY STAKEHOLDERS INCLUDING
Tashica Williams Amirgholizadeh, Ph.D.
Senior Associate General Counsel, IP,
IP Alliance and Due Diligence (IPADD), Team Lead
Gilead Sciences, Inc.
Anna L. Cocuzzo
Managing Counsel, Patents, Boston
Merck
William Vickery
Director of Due Diligence
Servier
This Year’s Highlights Include
- IP Policy Deep Dive: Understanding the wider implications of Loper on agency determinations as well as IP due diligence reviews in the life sciences
- Spotlight on Cellect and Xencor: analyzing new obviousness and means-plusfunction due diligence considerations
- Think Tank on Terminal Disclaimers and Double Patenting
- Focus on International Diligence Concerns from the UPC to the BIOSECURE Act
- New Administration Forecast: Anticipating How new Executive Branch leadership will impact IP due diligence strategies
PLUS! Two Exclusive Roundtables focusing on Dealmaking, Investing, and the IP Due Diligence Process Business Leaders and Investors let the cat out of the bag
PRE-CONFERENCE WORKSHOP
The New Life Sciences IP Due Diligence Checklist: Customizing Your IP Due Diligence Checklist to Account for Legal, Regulatory, and Policy Shifts Impacting the Life Sciences
Tuesday, 03 December, 2024
1:00 p.m.–4:30 p.m.
Workshop offered In-Person only.
About the Conference
ACI’s 7th Annual Summit on Life Sciences IP Due Diligence returns to Boston this December to bring you the critical information you need to develop winning strategies and ensure strong, valuable, and protected IP assets that can hold up under pressure.
Over the last year, a perfect legal and regulatory storm has been unleashed on the life sciences industry, greatly impacting IP due diligence.
From Supreme Court decisions such as Loper and Amgen, to the Federal Circuit’s rulings in Cellect and Xencor, to pending USPTO guidance on terminal disclaimers, charting a course through the choppy waters of IP due diligence is a real challenge in the life sciences arena. A strong IP portfolio, coupled with a forward-thinking due diligence strategy, will allow you to build the solid foundation you need to weather the storm and avoid disaster.
Redesign your IP Due Diligence Checklist for a tailored and bespoke approach that can withstand turbulent changes. This conference will bring you up-to-date on regulatory and policy changes, case law, and new and emerging technologies, including AI, that are having a profound effect on IP due diligence. With patent protection under the policy microscope, you’ll learn how to leverage a variety of IP protections, from traditional patents to trade secrets, to maintain valuable IP portfolios.
Get the inside scoop on red flags in diligence reviews, and avoid potential patent pitfalls — from ensuring training data ownership to avoiding the loss of a bundle of patents tied together by terminal disclaimers.
Work with your fellow practitioners on real-world problems to develop strategies and tools necessary to customize your IP due diligence approach. Learn to navigate through IP thickets, adjust for tectonic shifts in the life sciences landscape, and shore up IP value to maximize deal potential.
Hear first-hand how dealmakers and investors rely on IP due diligence at all stages. Industry stakeholders will explain what business leaders look for when making a deal and what diligence results may hinder investment.
For those newer to IP due diligence or looking to brush up on the latest tips and tricks, join us the day before the conference for our IP Due Diligence Checklist Workshop:
“The New Life Sciences IP Due Diligence Checklist: Customizing Your IP Due Diligence Checklist to Account for Legal, Regulatory, and Policy Shifts Impacting the Life Sciences.”
Register today to revamp your IP Due Diligence approach and safeguard your IP value.
SEE WHO ATTENDED IN THE PAST
- AMRI
- Allergan plc
- AtriCure Inc
- Azurity Pharmaceuticals Inc
- BONWRx
- Beck & Thomas
- Biogen
- Blaze Bioscience Inc
- BlueRock Therapeutics
- Boehringer Ingelheim International GmbH
- Boston University (CARB-X)
- Brammer Bio
- Brinks Gilson & Lione
- Centre for Drug Research and Development
- Cipla Limited
- Clexio Biosciences
- Codiak BioSciences
- Dana-Farber Cancer Institute Venture Fund, Binnery Street Capital
- DRI Capital Inc
- Dentsply Sirona Inc
- Dr. Reddys Laboratories
- Dyno Therapeutics
- Eisai Inc
- Eli Lilly & Co
- Evolve BioSystems
- Ferring Pharmaceuticals
- Foghorn Therapeutics
- Forma Therapeutics Inc
- Futuragene
- Genfit
- Genentech Inc
- Gilead Sciences
- Gurnet Point Capital
- Heliae
- Hexos Renewals
- Hikma Pharmaceuticals USA Inc
- Hoyng Rokh Monegier
- Immunogen Inc
- Incyte Corporation
- Indivior Inc
- Intellia Therapeutics Inc
- Ipsen Bioscience Inc
- Ironwood Pharmaceuticals Inc
- Jazz Pharmaceuticals
- Johnson & Johnson
- Jounce Therapeutics Inc
- KSQ Therapeutics Inc
- MEDRx
- Merchant & Gould
- Merck & Co
- Mersana Therapeutics
- MicroVention Inc.
- Novartis
- Obalon Therapeutics
- Pieris Pharmaceuticals Inc
- Purdue Pharma LP
- Regeneron Pharmaceuticals Inc
- ReNAgade Therapeutics
- Roivant Sciences Inc
- Rutgers Law School
- SalioGen Therapeutics
- Sanofi
- Sarepta Therapeutics
- Science Exchange
- Servier Pharmaceuticals LLC
- Shire Pharmaceuticals
- SmartPharm Therapeutics
- Sumitomo Pharma America Inc
- Taro Pharmaceutical Industries
- Teva Pharmaceuticals
- Third Rock Ventures
- Transformative
- Treeline Biosciences
- US Court of Appeals for Federal Circuit
- VBI Vaccines Inc
- Viatris
- VLP Law Group LLP
- Wave Life Sciences
- Zentalis Pharmaceuticals
Testimonials
Unique high level sessions, good mix of in-house and outside counsel.
Hearing from professionals involved in due diligence on a daily basis was very informative.
Great panels, lots of diversity of practice, and lots of seasoned practitioners.
The design of the event brought us all together along with room intimacy.